ReviewDrugs2010
Advances in the pharmacological management of Huntington's disease.
Review in Drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 69 citations in OpenAlex.
- Short-term Classification of Neurodegenerative Diseases using Time-series Features Based on Analysis of Gait Dynamics.Journal of biomedical physics & engineering · 2026Article
- 6-Aminoflavone Activates Nrf2 to Inhibit the Phospho-JNK/TNF-α Signaling Pathway to Reduce Amyloid Burden in an Aging Mouse Model.ACS omega · 2023Article
- Novel EAAT2 activators improve motor and cognitive impairment in a transgenic model of Huntington's disease.Frontiers in behavioral neuroscience · 2023Article
- MicroRNAs in Huntington's Disease: Diagnostic Biomarkers or Therapeutic Agents?Frontiers in cellular neuroscience · 2021Review
- Perceptions of the impact of chorea on health-related quality of life in Huntington disease (HD): A qualitative analysis of individuals across the HD spectrum, family members, and clinicians.Neuropsychological rehabilitation · 2020Article
- MicroRNAs in Neurocognitive Dysfunctions: New Molecular Targets for Pharmacological Treatments?Current neuropharmacology · 2017Review
- Review
- Synthesis of (±)-Tetrabenazine by Visible Light Photoredox Catalysis.The Journal of organic chemistry · 2015Article
- Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease.Pharmacological reviews · 2015Review
- Diffusion weighted imaging of prefrontal cortex in prodromal Huntington's disease.Human brain mapping · 2014Article
- Treatment of Huntington's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2014Review
- Localization and expression of VMAT2 aross mammalian species: a translational guide for its visualization and targeting in health and disease.Advances in pharmacology (San Diego, Calif.) · 2013Review
- Extracts of adipose derived stem cells slows progression in the R6/2 model of Huntington's disease.PloS one · 2013Article
- Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's Disease.Journal of Huntington's disease · 2012Article
- Tetrabenazine: for chorea associated with Huntington's disease.CNS drugs · 2011Article
- The role of immunity in Huntington's disease.Molecular psychiatry · 2011Review
- The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease.The Journal of clinical investigation · 2011Review
- Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease.Neuropsychiatric disease and treatment · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is inevitable physical, cognitive and behavioural decline in Huntington's disease (HD), a dominantly inherited progressive neurological disorder. The hallmark of the disease is chorea, an involuntary brief movement that tends to flow between body regions. HD is diagnosed clinically with genetic confirmation. Predictive testing is available; however, it should be undertaken with caution in patients at risk for the disease but without clinical disease expression. Ongoing observational trials have identified not only early subtle motor signs, but also striatal volume, verbal memory and olfaction as possible early manifestations of clinical disease. Multiple areas of the brain degenerate, with dopamine, glutamate and GABA being the predominant neurotransmitters affected in HD. Although many pharmacotherapies have been evaluated targeting these neurotransmitters, few well conducted trials for symptomatic or neuroprotective interventions have yielded positive results. Tetrabenazine is one of the better studied and more effective agents for reducing chorea, although with a risk of potentially serious adverse effects. Newer antipsychotic agents such as olanzapine and aripiprazole may have adequate efficacy with a more favourable adverse-effect profile than older antipsychotics for treating chorea and psychosis. In this review, the pathogenesis, epidemiology and diagnosis of HD are discussed as background for understanding potential pharmacological treatment options. Potential strategies to delay the progression of HD that have been studied and are planned for the future are summarized. Although there is no current method to change the course of this devastating disease, education and symptomatic therapies are effective tools available to clinicians and the families affected by HD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.